PL1928840T3 - 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej - Google Patents

1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej

Info

Publication number
PL1928840T3
PL1928840T3 PL06725326T PL06725326T PL1928840T3 PL 1928840 T3 PL1928840 T3 PL 1928840T3 PL 06725326 T PL06725326 T PL 06725326T PL 06725326 T PL06725326 T PL 06725326T PL 1928840 T3 PL1928840 T3 PL 1928840T3
Authority
PL
Poland
Prior art keywords
carboxamides
pyrazole
beta
preparation
hydroxysteroid dehydrogenase
Prior art date
Application number
PL06725326T
Other languages
English (en)
Inventor
Paul Gillespie
Jr Robert Alan Goodnow
Qiang Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1928840T3 publication Critical patent/PL1928840T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06725326T 2005-04-05 2006-03-27 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej PL1928840T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66836705P 2005-04-05 2005-04-05
PCT/EP2006/061057 WO2006106052A1 (en) 2005-04-05 2006-03-27 Pyrazoles
EP06725326A EP1928840B1 (en) 2005-04-05 2006-03-27 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
PL1928840T3 true PL1928840T3 (pl) 2012-01-31

Family

ID=36514279

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06725326T PL1928840T3 (pl) 2005-04-05 2006-03-27 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej

Country Status (21)

Country Link
US (1) US7345058B2 (pl)
EP (1) EP1928840B1 (pl)
JP (1) JP4880671B2 (pl)
KR (1) KR100931411B1 (pl)
CN (1) CN101155783B (pl)
AR (1) AR053203A1 (pl)
AT (1) ATE519744T1 (pl)
AU (1) AU2006232660B2 (pl)
BR (1) BRPI0610459A2 (pl)
CA (1) CA2602781C (pl)
DK (1) DK1928840T3 (pl)
ES (1) ES2369389T3 (pl)
IL (1) IL186118A0 (pl)
MX (1) MX2007012212A (pl)
NO (1) NO20074872L (pl)
PL (1) PL1928840T3 (pl)
PT (1) PT1928840E (pl)
RU (1) RU2381217C2 (pl)
TW (1) TWI309645B (pl)
WO (1) WO2006106052A1 (pl)
ZA (1) ZA200708419B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
MY149622A (en) * 2006-03-22 2013-09-13 Hoffmann La Roche Pyrazoles as 11-beta-hsd-1
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008011453A2 (en) * 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
EP2163543B1 (en) * 2007-05-18 2015-03-04 Shionogi&Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity
WO2009010416A2 (en) 2007-07-17 2009-01-22 F. Hoffmann-La Roche Ag Inhibitors of 11b-hydroxysteroid dehydrogenase
FR2924931B1 (fr) * 2007-12-12 2010-01-15 Oreal Utilisations de derives 1-°(1h-pyrazol-4-y!heterocycliques pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute ; nouveaux composes ; compositions les contenant.
AU2009211215B2 (en) * 2008-02-04 2011-11-03 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
AR078887A1 (es) * 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
BR112014031785A2 (pt) 2012-06-20 2017-06-27 Hoffmann La Roche composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
PL3074011T3 (pl) * 2013-11-25 2020-01-31 Corcept Therapeutics Incorporated Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego
US9273254B2 (en) * 2013-12-20 2016-03-01 Ecolab Usa Inc. Amino acetals and ketals as hydrogen sulfide and mercaptan scavengers
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated THERAPEUTIC USES OF RELACORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR DERIVED FROM AZADECALIN FUSED TO A HETEROARYL KETONE
MX2022006633A (es) 2019-12-11 2022-06-24 Corcept Therapeutics Inc Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant.
IL298151A (en) * 2020-05-27 2023-01-01 Corcept Therapeutics Inc Concomitant Administration of a Recorrelating Glucocorticoid Receptor Modulator and Cyp2c8 Substrates
CN114560811B (zh) * 2022-03-11 2023-09-01 上海立森印迹医药技术有限公司 1,3,5-三取代-吡唑-4羧酸衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA210876A (de) 1975-03-25 1979-01-15 Byk Gulden Lomberg Chem Fab Verfahren zur herstellung von neuen nidrofuryl- pyrazolderivaten
US4620865A (en) 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
JPH0768220B2 (ja) * 1986-04-24 1995-07-26 三井東圧化学株式会社 新規ピラゾ−ル誘導体、その製造法およびそれらを含有する農園芸用殺菌剤
US4792565A (en) * 1986-04-24 1988-12-20 Mitsui Toatsu Chemicals, Inc. Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
IL91418A (en) * 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2002003410A (ja) 2000-06-27 2002-01-09 Fuji Photo Film Co Ltd 芳香族ハロゲン化物の製造方法。
EP1337508A1 (en) 2000-11-28 2003-08-27 Pfizer Products Inc. Preparation of sodium-hydrogen exchanger type-1 inhibitors
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
PL370111A1 (pl) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitory dehydrogenazy 11-beta-hydroksysteroidów typu I
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
KR20050044517A (ko) 2001-11-22 2005-05-12 바이오비트럼 에이비 11-베타-히드록시 스테로이드 탈수소효소 유형 1 의억제제
WO2003051845A1 (en) 2001-12-19 2003-06-26 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
US20050171161A1 (en) 2002-03-06 2005-08-04 Fong Tung M. Method of treatment or prevention of obesity
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004011410A1 (en) 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds
CA2501611A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
US20060058315A1 (en) 2002-11-07 2006-03-16 Astrazeneca Ab 2-Oxo-ethanesulfonamide derivates
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
ATE476425T1 (de) 2003-05-29 2010-08-15 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
SE0301883D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
JP2007501789A (ja) * 2003-08-07 2007-02-01 メルク エンド カムパニー インコーポレーテッド 11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのピラゾールカルボキサミド
US7517900B2 (en) * 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators

Also Published As

Publication number Publication date
ES2369389T3 (es) 2011-11-30
MX2007012212A (es) 2007-12-07
RU2381217C2 (ru) 2010-02-10
AU2006232660A1 (en) 2006-10-12
JP2008534647A (ja) 2008-08-28
EP1928840A1 (en) 2008-06-11
DK1928840T3 (da) 2011-09-12
NO20074872L (no) 2007-10-30
CA2602781C (en) 2011-02-08
TWI309645B (en) 2009-05-11
KR100931411B1 (ko) 2009-12-10
TW200643013A (en) 2006-12-16
CA2602781A1 (en) 2006-10-12
KR20070108937A (ko) 2007-11-13
IL186118A0 (en) 2008-01-20
WO2006106052A1 (en) 2006-10-12
ATE519744T1 (de) 2011-08-15
AU2006232660B2 (en) 2010-03-25
PT1928840E (pt) 2011-10-03
BRPI0610459A2 (pt) 2010-06-22
US20060223852A1 (en) 2006-10-05
US7345058B2 (en) 2008-03-18
JP4880671B2 (ja) 2012-02-22
CN101155783B (zh) 2012-01-04
EP1928840B1 (en) 2011-08-10
ZA200708419B (en) 2008-11-26
CN101155783A (zh) 2008-04-02
AR053203A1 (es) 2007-04-25
RU2007140737A (ru) 2009-05-20

Similar Documents

Publication Publication Date Title
PT1928840E (pt) 1h-pirazole-4-carboxamidas, a sua preparação e a sua utilização a título de inibidores de 11-betahidroxiesteróide desidrogenase
HK1209729A1 (en) Compounds, compositions and methods
IL191655A0 (en) Novel compounds, their preparation and use
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
IL183740A0 (en) Cyclohexylamides as dopamine d3, d2 and
ZA200709854B (en) 17ß-HSD1 and STS inhibitors
GB0601143D0 (en) Uses, methods and compositions
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0616111D0 (en) Agents, methods and uses
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
EP1908786A4 (en) 2-cyanoacrylate
GB0706077D0 (en) Methods, Compositions and uses thereof
EP1961753A4 (en) DERIVATIVES OF PIRAZOLOPYRIMIDINONE, THEIR PREPARATION AND USE
GB0511190D0 (en) Use
GB0819432D0 (en) Compound, composition and use
EP2020426A4 (en) FOAM, COMPOSITION FOR FOAM AND USE OF FOAM
TWI367222B (en) Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0519047D0 (en) Applicator, kit, and process
GB0502250D0 (en) Use
GB0607562D0 (en) Method, composition and use
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
GB0506496D0 (en) Compound, composition and use